| 1. |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, Eln115727) in Patients with Mild to Moderate Alzheimer?s Disease Who are Apolipoprotein Eέ4 Non-Carriers. (Elan 301 study) |
| 2. |
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients with Mild to Moderate Alzheimer's Disease. (Toyama study) |
| 3. |
CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluation Dimebon in Patients with Mild-to-Moderate Alzheimer?s Disease on Donepezil |
| 4. |
A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatments of Mild-to-Moderate Alzheimer?s disease. |
Email this page
